FDA Clearance Tracker · P220029-S002
Optilume BPH Catheter System
Last checked: Nov 20, 2026Latest source record: Aug 15, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Aug 15, 2024
Approved
Time to decision
86 days
Received May 21, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P220029-S002
- Device name
- Optilume BPH Catheter System
- Applicant
- Urotronic, Inc.
- Applicant location
- Minneapolis, MN
- Received
- May 21, 2024
- Decided
- Aug 15, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P220029
Device type
- Device class
- Class III
- Specialty
- GI, Urology & NephrologyUrology
FDA's approval statement
As written in FDA's record.
approval for a change in supplier for two kit components (i.e., the Tuohy-Borst adapter and stopcock), a change in kit packaging of the components (i.e., addition of the Tuohy-Borst adapter and Stopcock to the Pre-Dilation Catheter Tyvek Pouch), and a change in labeling to remove the vascular meta-analysis information from the Instructions for Use
Source documents
Other decisions for Urotronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K250910 · Decided May 22, 2025 · 57 days after receipt
Device type: Dilator, Catheter, Ureteral (EZN) · GI, Urology & Nephrology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.